Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of SHR-A2102, indicating progress in its drug development pipeline [1] Group 1: Drug Information - Drug Name: SHR-A2102 [1] - Dosage Form: Injection [1] - Application Type: Clinical trial [1] - Acceptance Numbers: CXSL2500879, CXSL2500881 [1] Group 2: Clinical Trial Details - The approval allows for two clinical trials: 1. A trial combining SHR-A2102 with Vedolizumab in patients with advanced solid tumors [1] 2. A trial assessing the safety, tolerability, and efficacy of SHR-A2102 combined with Atezolizumab or other PD-(L)1 inhibitors in patients with locally advanced or metastatic esophageal cancer [1] - The trials are categorized as multicenter, open-label, Phase I/II studies [1] Group 3: Regulatory Approval - The clinical trial applications were reviewed and approved based on the requirements of the Drug Administration Law of the People's Republic of China [1] - The approval was granted for applications received on October 13 and 14, 2025 [1]